Tag:
Daniel Vasella
Latest Headlines
Latest Headlines
Busy Novartis announces layoffs, taps new CFO, and slashes chairman's pay
While the U.S. government was announcing its kickbacks lawsuit against Novartis, the Swiss drugmaker was putting the finishing touches on a few press releases of its own.
Updated: EU pharma CEOs earned 46% less than U.S. peers
CEO pay in Europe continues to be a flashpoint given the high unemployment and austerity measures the workaday folk on the continent face. Still, a new analysis shows the CEO's of European drugmakers continue to pull in far less than their U.S. counterparts.
Swiss prosecutor weighs charges against Novartis directors, ex-chairman
The court of public opinion passed quick judgment on Novartis and its 72-million-franc payout for departing chairman Daniel Vasella. The Swiss quickly said no, non and nein to that idea, and the company quickly abandoned that non-compete deal. But will an actual court have its chance to rule?
Reports: Ex-Novartis chief Vasella to flee Switzerland for US
Swiss media report that Vasella is decamping from his home in Zug for greener pastures in the U.S.
Shocking exit bonus for a departing chief? Not us, Roche says
Outgoing Roche Chairman Franz Humer will get a bonus when he leaves next year, Vice Chairman Andre Hoffman told shareholders. But it will be "completely different" from the $76 million fellow Swiss drugmaker Novartis originally planned to pay ex-chairman Daniel Vasella.
Board, Vasella slammed for handling of retirement prize
Like the naughty child that gets caught doing something wrong, Novartis ($NVS) keeps changing its story about just what it is up to. The Swiss company that succumbed to pressure this week and revoked a proposed $78 million non-compete to departing Chairman Daniel Vasella now says it will hire him as a consultant.
UPDATED: Novartis nixes $78M non-compete with Vasella
The news of Daniel Vasella's $78 million payoff from Novartis couldn't have surfaced at a worse time. Once again, the Swiss drugmaker becomes a lightning rod for executive-pay watchdogs. And now, lightning is striking just days before the Swiss are due to vote on a proposal designed to rein in executive compensation.
Novartis CEO: Don't expect us to slay Vasella's pets
With a new chairman selected to take the helm of Novartis ($NVS), lots of folks are wondering what is in store for the Swiss drugmaker. Not so fast, CEO Joe Jimenez said this week.
Novartis welcomes ex-COO as chairman
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...
Novartis' Jimenez says no need to sell Roche stake
With a new chairman selected to take the helm of Novartis, lots of folks are wondering what is in store for the Swiss drugmaker. Not so fast, CEO Joe Jimenez said this week.
